Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Diabetes in Developing Countries
Published in: International Journal of Diabetes in Developing Countries 2/2020

01-04-2020 | Diabetes | Original Article

Association of SRB1 and PON1 gene polymorphisms with type 2 diabetes mellitus: a case control study

Authors: Mohd Wamique, Wahid Ali, Dandu Himanshu

Published in: International Journal of Diabetes in Developing Countries | Issue 2/2020

Login to get access

Abstract

Objective

Single-nucleotide polymorphism (SNP) in Paraoxonase 1 (PON1) and scavenger receptor class b member 1 (SRB1) gene has been associated with impairing high-density lipoprotein (HDL) functionality as an antioxidant and shown to diminish ability of PON1 in cholesterol homeostasis. Several studies found that SRB1 and PON1 polymorphism increases T2DM risk. Our study aimed to investigate the association and susceptibility of polymorphic variants in SRB1 rs9919713 and PON1 rs662 with type 2 diabetes mellitus.

Methods

In the present case-control study, 250 type 2 diabetes mellitus patients (T2DM) and 250 healthy volunteer were recruited. The genotypes of PON1 and SRB1 were determined by using polymerase chain reaction-restriction fragment length polymorphism (RFLP-PCR) technique, and biochemical analysis was done using standard protocol.

Results

C and R alleles showed significant association with T2DM susceptibility with an odds ratio of 1.42 (p < 0.005) and 1.40 (p < 0.007), respectively. The frequency of CC and RR genotype was significantly higher in T2DM patients compared with healthy controls. Furthermore, CC and RR genotypes were significantly associated with higher LDL and low HDL levels. Additionally, no other significant association was observed.

Conclusions

We conclude that the PON1 and SRB1 gene polymorphisms may probably surrogate biomarkers for T2DM susceptibility.
Literature
1.
Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Australas Med J. 2014;7(1):45–8.CrossRef
2.
Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes. 1996;45(3 SUPPL):27–30.CrossRef
3.
Cerda Á, et al. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin. Clin Chim Acta. 2010;411(9–10):631–7.CrossRef
4.
Prasad RB, Groop L. Genetics of type 2 diabetes—pitfalls and possibilities. Genes (Basel). 2015;6(1):87–123.CrossRef
5.
Gomathi P, Iyer AC, Murugan PS, Sasikumar S, Raj NBAJ, Ganesan D, et al. Association of paraoxonase-1 gene polymorphisms with insulin resistance in south Indian population. Gene. 2018;650:55–9.CrossRef
6.
Flekac M, Skrha J, Zídková K, Lacinová Z, Hilgertová J. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res. 2008;57(5):717–26.PubMed
7.
Asmat U, Abad K, Ismail K. Diabetes mellitus and oxidative stress—a concise review. Saudi Pharm J. 2016;24(5):547–53.CrossRef
8.
Jayashree S, Arindam M, Vijay KV. Genetic epidemiology of coronary artery disease: an Asian Indian perspective. J Genet. 2015;94(3):539–49.
9.
Macharia M, Kengne AP, Blackhurst DM, Erasmus RT, Matsha TE. Paraoxonase1 genetic polymorphisms in a mixed ancestry African population. Mediat Inflamm. 2014;2014.
10.
Gokcen S. Serum paraoxonase levels and PON1(192) polymorphism in type 2 diabetes mellitus patients. Gazi Med J. 2013;24(3):70–3.CrossRef
11.
McCarthy JJ, et al. Polymorphisms of the scavenger receptor class B member 1 are associated with insulin resistance with evidence of gene by sex interaction. J Clin Endocrinol Metab. 2009;94(5):1789–96.CrossRef
12.
Care D, Suppl SS. 2. Classification and diagnosis of diabetes: standards of medical care in diabetesd2019. Diabetes Care. 2019;42(january):S13–28.
13.
Kannan S, Mahadevan S, Ramji B, Jayapaul M, Kumaravel V. LDL-cholesterol: Friedewald calculated versus direct measurement-study from a large Indian laboratory database. Indian J Endocrinol Metab. 2014;18(4):502.CrossRef
14.
Gupta N, Binukumar BK, Singh S, Sunkaria A, Kandimalla R, Bhansali A, et al. Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a north-west Indian population. Gene. 2011;487(1):88–95.CrossRef
15.
Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. Ann Hum Genet. 2002;66(2):111–124.
16.
Yin RX, Wu DF, Aung LH, Yan TT, Cao XL, Long XJ, et al. Several lipid-related gene polymorphisms interact with overweight/obesity to modulate blood pressure levels. Int J Mol Sci. 2012;13(9):12062–81.CrossRef
17.
Bhaskar S, Ganesan M, Chandak GR, Mani R, Idris MM, Khaja N, et al. Association of PON 1 and APOA 5 gene polymorphisms in a cohort of Indian patients having coronary artery disease with and without type 2 diabetes. Genet Test Mol Biomarkers. 2011;15(7–8):507–12.CrossRef
18.
Shakeri R, Khajeniazi S, Marjani A. Association between promoter polymorphism (− 108C > T) of paraoxonase1 gene and it’s paraoxonase activity in patients with Type2 diabetes in northern Iran. Clin Chim Acta. 2017;474(August):34–7.CrossRef
19.
Agachan B, Yilmaz H, Ergen HA, Karaali ZE, Isbir T. Paraoxonase (PON1) 55 and 192 polymorphism and its effects to oxidant-antioxidant system in Turkish patients with type 2 diabetes mellitus. Physiol Res. 2005;54(3):287–93.PubMed
20.
Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond). 2000;98:355–63.CrossRef
21.
Alharbi KK, Khan IA, al-Daghri NM, Munshi A, Sharma V, Mohammed AK, et al. ABCA1 C69T gene polymorphism and risk of type 2 diabetes mellitus in a Saudi population. J Biosci. 2013;38(5):893–7.CrossRef
22.
El-Lebedy D, Kafoury M, Abd-El Haleem D, Ibrahim A, Awadallah E, Ashmawy I. Paraoxonase-1 gene Q192R and L55M polymorphisms and risk of cardiovascular disease in Egyptian patients with type 2 diabetes mellitus. J Diabetes Metab Disord. 2014;13(1):1–7.CrossRef
23.
Khodaeian M, Enayati S, Tabatabaei-malazy O, Amoli MM. Association between genetic variants and diabetes mellitus in Iranian populations : a systematic review of observational studies. J Diabetes Res. 2015;2015:585917.
24.
Wamique M, Ali W, Reddy DH, Vishwakarma P, Waseem M. A case control study on HDL associated PON1 enzyme level in northern Indian type 2 diabetes mellitus patients. Diabetes Metab Syndr Clin Res Rev. 2018;12(6):843–847.
25.
Mccarthy JJ, et al. Polymorphisms of the scavenger receptor class B member 1 are associated with insulin resistance with evidence of gene by sex interaction. J Clin Endocrinol Metab. 2009;94(5):1789–96.
26.
Goodarzynejad H, Boroumand M, Behmanesh M, Ziaee S, Jalali A. The rs5888 single nucleotide polymorphism in scavenger receptor class B type 1 (SCARB1) gene and the risk of premature coronary artery disease: a case-control study. Lipids Health Dis. 2016;15(1):1–9.CrossRef
27.
Osgood D, Corella D, Demissie S, Cupples LA, Wilson PW, Meigs JB, et al. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the Framingham study. J Clin Endocrinol Metab. 2003;88(6):2869–79.CrossRef
28.
ArulJothi KN, et al. Molecular analysis of the LDLR gene in coronary artery disease patients from the Indian population. Clin Biochem. 2016;49(9):669–674.
29.
Wu D-F, et al. Association of rs5888 SNP in the scavenger receptor class B type 1 gene and serum lipid levels. Lipids Health Dis. 2012;11(1):50.CrossRef
30.
Tetik Vardarlı A, Harman E, Bozok Çetintaş V, et al. Polymorphisms of lipid metabolism enzyme-coding genes in patients with diabetic dyslipidemia. Anatol J Cardiol. 2017;17(4):313–21.
Metadata
Title
Association of SRB1 and PON1 gene polymorphisms with type 2 diabetes mellitus: a case control study
Authors
Mohd Wamique
Wahid Ali
Dandu Himanshu
Publication date
01-04-2020
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 2/2020
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-019-00787-2

Other articles of this Issue 2/2020

International Journal of Diabetes in Developing Countries 2/2020 Go to the issue

Review Article

A systematic review of the effect of sleep apnea syndrome and its therapy on HbA1c in type 2 diabetes

Original Article

Changes in SFRP5, WNT5A, HbA1c, BMI, PBF, and insulin resistance in men with type 2 diabetes after 12 weeks of combined exercise (HIIT and resistance)

Original Article

High-fat diet with alcohol elevate oxidative stress which cause hyperlipidemia by inducing mutation in the ANGPTL3 locus

Original Article

Mild hyperamylasemia in type 1 diabetic children without diabetic ketoacidosis is associated with C-peptide

Editorial

Post COVID-19 diabetes care—lessons and challenges

Original Article

Phenotypic characterization of patients with type 2 diabetes mellitus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits